预防性用药经验与个人风险态度在三联血管筛查未参与中的作用
基于VIVA筛查试验中25078名男性的病例对照研究,探讨预防性用药和个人风险态度与未参与腹主动脉瘤、外周动脉疾病和高血压三联筛查的关系。他汀类(0.78)、抗高血压药(1.26)和抗血栓药(1.13)使用均与未参与相关;无近期心血管病诊断的预防性用药者未参与风险较低(0.82)。作者认为可按受邀者特征调整风险沟通并针对健康素养较低者提供干预。
要点
- 他汀类使用与未参与三联血管筛查相关(OR 0.78,95%CI 0.71-0.85)。
- 抗高血压药(OR 1.26)和抗血栓药(OR 1.13)使用与未参与相关。
- 无近期心血管病诊断的预防性用药者未参与风险较低(OR 0.82,95%CI 0.72-0.94)。
核心结论
- 三联血管筛查未参与受预防性用药使用和传统解释因素(包括现存心血管病共病)影响。
- 作者认为按受邀者特征和临床风险场景调整风险沟通、并针对健康素养较低者提供干预,可能有助于参与率。
研究设计与样本
- 病例对照研究,嵌套于VIVA筛查试验,该试验向25078名男性提供腹主动脉瘤、外周动脉疾病和高血压筛查与干预。
- 社会人口学、社会经济特征、诊断和预防性用药数据来自国家登记库,并构建个人风险态度的替代指标,采用逻辑回归估计OR及95%CI。
主要发现
- 他汀类使用与未参与相关(OR 0.78,95%CI 0.71-0.85)。
- 抗高血压药使用与未参与相关(OR 1.26,95%CI 1.13-1.41)。
- 抗血栓药使用与未参与相关(OR 1.13,95%CI 1.04-1.23)。
- 无近期心血管病诊断的预防性用药者与未参与存在统计学显著关联(OR 0.82,95%CI 0.72-0.94)。
- 低社会经济地位和共病等传统解释未参与的因素得到确认。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-attendance for vascular screening potentially restricts the overall benefit of screening at population level, but may be the result of rational judgment on the part of invitees who might not consider their risk to be relevant. The aim of this study was to investigate the role of current use of preventive medication and personal risk attitude as potential factors explaining non-attendance at triple vascular screening. METHODS: This was a case control study across 25,078 men offered screening and intervention for abdominal aortic aneurysm, peripheral artery disease, and hypertension in the Viborg Vascular (VIVA) screening trial. Data on socio-demographic and socio-economic characteristics, diagnoses, and use of preventive medication were extracted from national registries. A proxy for personal risk attitude was constructed. Logistic regression was used to estimate odds ratios with 95% confidence intervals. RESULTS: Use of statins (0.78; 95% CI 0.71-0.85), antihypertensives (1.26, 95% CI 1.13-1.41), or antithrombotics (1.13, 95% CI 1.04-1.23) were all associated with non-attendance. With regards to personal risk attitude, a statistically significant association was found between users of preventive medication with no recent diagnosis of cardiovascular disease and non-attendance (0.82, 95% CI 0.72-0.94). The role of traditional factors explaining non-attendance at vascular screening, such as low socio-economic status and comorbidity, was confirmed. CONCLUSION: Non-attendance at triple vascular screening is influenced by use of preventive medications and traditional explanatory factors of non-attendance at vascular screening, including existing CVD comorbidity. Attendance rates might benefit from rethinking risk communication alongside screening invitations according to varying invitee profiles and clinical risk scenarios, and from providing interventions targeted at individuals with lower levels of health literacy.
引用
- Hansen TB, Lindholt JS, Søgaard R, et al. Role of Experience With Preventive Medication and Personal Risk Attitude in Non-Attendance at Triple Vascular Screening. Eur J Vasc Endovasc Surg. 2018. PMID: 29891436. doi:10.1016/j.ejvs.2018.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。